Cashel Neural, a small molecule biotech startup spun out of Cleveland Clinic’s Lerner Research Institute, said it has raised funding that will enable further development of specific molecules that can help make new myelin in multiple sclerosis (MS) patients.
The funds come from the Fast Forward program, a nonprofit organization established by the National Multiple Sclerosis Society to support commercial organizations engaged in the development of new therapies and diagnostic tools for MS, according to a news release.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutré.
Originally published February 12, 2019.